However, despite the pro-atherogenic effect and prediction of adverse events, the inhibition of Lp-PLA2 with darapladib, the most advanced and most widely studied Lp-PLA2 inhibitor, has failed to provide substantial benefits in patients with stable CAD [152] and admitted for an ACS [89]. Here, PLA2G7 is linked to coronary artery disorder.